Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients

Published:2016-04-26 Issue:5 Volume:107 Page:590-600
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Iwasa Satoru¹,Yamada Yasuhide¹,Heike Yuji²,Shoji Hirokazu¹,Honma Yoshitaka¹,Komatsu Nobukazu³,Matsueda Satoko⁴,Yamada Akira⁵,Morita Michi⁶⁷,Yamaguchi Rin⁷,Tanaka Natsuki⁸,Kawahara Akihiko⁹,Kage Masayoshi⁵⁹,Shichijo Shigeki⁴,Sasada Tetsuro¹⁰,Itoh Kyogo⁴

Affiliation:

1. Gastrointestinal Medical Oncology Division National Cancer Center Hospital TokyoJapan

2. Immunotherapy and Cell Therapy Department St. Lucas International Hospital TokyoJapan

3. Department of Immunology Kurume University School of Medicine KurumeJapan

4. Cancer Vaccine Center Kurume University KurumeJapan

5. Research Center for Innovative Cancer Therapy Kurume University School of Medicine KurumeJapan

6. Department of Surgery Nagasaki University Graduate School of Biomedical Sciences NagasakiJapan

7. Division of Pathology Medical Center of Kurume University KurumeJapan

8. Department of Surgery Kurume University School of Medicine KurumeJapan

9. Department of Diagnostic Pathology Kurume University Hospital KurumeJapan

10. Cancer Vaccine Center Kanagawa Cancer Center Institute Yokohama Japan

Funder

Ministry of Education, Culture, Sports, Science, and Technology

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12919

Reference20 articles.

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

3. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

4. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin

5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma;Molecular Cancer Therapeutics;2024-01-11

2. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model;Gastroenterology;2021-10

3. Evaluation of the Immunological Response of Childhood Cancer Patients Treated with a Personalized Peptide Vaccine for Refractory Soft Tissue Tumor: A Four-Case Series;The Kurume Medical Journal;2021-06-30

4. First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors;Cancer Science;2021-02-25

5. Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects;Journal of Immunology Research;2020-10-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3